MANNITOL 20 POUR CENT B. BRAUN, solution injectable hypertonique pour perfusion en flacon verre Frankrike - fransk - ANSM (Agence Nationale de Sécurité du Médicament et des Produits de Santé)

mannitol 20 pour cent b. braun, solution injectable hypertonique pour perfusion en flacon verre

laboratoire b braun medical - mannitol 20 g - solution - 20 g - pour 100 ml de solution injectable > mannitol 20 g - solution produisant une diurese osmotique (b: sang et organes hématopoïétiques) - classe pharmacothérapeutique solution produisant une diurese osmotique (b: sang et organes hématopoïétiques). - code atc : b05bc01mannitol 20 pour cent b braun, solution injectable hypertonique pour perfusion en flacon de verre est une solution pour perfusion qui est administrée par goutte-à-goutte en intraveineuse.ce médicament est indiqué pour: protéger vos reins en conservant ou en augmentant votre débit urinaire, réduire la pression ou le volume de liquide à l'intérieur de votre crâne, augmenter le débit urinaire en cas d'intoxication afin de stimuler l'excrétion des substances toxiques, renforcer votre traitement si vous souffrez d'une crise de glaucome aigu.

Mannitol 15 % w/v Viaflo inf. opl. i.v. Belgia - nederlandsk - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

mannitol 15 % w/v viaflo inf. opl. i.v.

baxter sa-nv - mannitol 15 g/100 ml - oplossing voor infusie - mannitol

Mannitol 15 % w/v Viaflo inf. opl. i.v. Belgia - nederlandsk - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

mannitol 15 % w/v viaflo inf. opl. i.v.

baxter sa-nv - mannitol 15 g/100 ml - oplossing voor infusie - mannitol

Mannitol 15 % w/v Viaflo sol. perf. i.v. Belgia - fransk - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

mannitol 15 % w/v viaflo sol. perf. i.v.

baxter sa-nv - mannitol 15 g/100 ml - solution pour perfusion - mannitol

Mannitol 15 % w/v Viaflo sol. perf. i.v. Belgia - fransk - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

mannitol 15 % w/v viaflo sol. perf. i.v.

baxter sa-nv - mannitol 15 g/100 ml - solution pour perfusion - mannitol

Mannitol Intravenous Infusion BP 20% w/v Solution for Infusion Irland - engelsk - HPRA (Health Products Regulatory Authority)

mannitol intravenous infusion bp 20% w/v solution for infusion

baxter healthcare limited - mannitol - solution for infusion - 20 percent weight/volume - solutions producing osmotic diuresis; mannitol

Mannitol 15% w/v solution for infusion Irland - engelsk - HPRA (Health Products Regulatory Authority)

mannitol 15% w/v solution for infusion

baxter holding b.v. - mannitol - solution for infusion - 15 percent weight/volume - solutions producing osmotic diuresis; mannitol

MANNITOL injection, solution USA - engelsk - NLM (National Library of Medicine)

mannitol injection, solution

fresenius kabi usa, llc - mannitol (unii: 3owl53l36a) (mannitol - unii:3owl53l36a) - mannitol injection, usp is indicated for the following therapeutic uses: • the promotion of diuresis, in the prevention and/or treatment of the oliguric phase of acute renal failure before irreversible renal failure becomes established.  • the reduction of intracranial pressure and treatment of cerebral edema by reducing brain mass.  • the reduction of elevated intraocular pressure when it cannot be lowered by other means.  • the promotion of urinary excretion of toxic substances. mannitol solution, 2.5% is indicated as an irrigation solution in transurethral prostatic resection or other transurethral surgical procedures. • well established anuria due to severe renal disease.  • severe pulmonary congestion or frank pulmonary edema.  • active intracranial bleeding except during craniotomy.  • severe dehydration.  • progressive renal damage or dysfunction after institution of mannitol therapy, including increasing oliguria and azotemia.  • progressive heart failure or pulmonary congestion after mannitol therapy

MANNITOL injection, solution USA - engelsk - NLM (National Library of Medicine)

mannitol injection, solution

hospira, inc. - mannitol (unii: 3owl53l36a) (mannitol - unii:3owl53l36a) - mannitol intravenous (mannitol injection, usp) is indicated for the following purposes in adults and pediatric patients. - reduction of intracranial pressure and brain mass. - reduction of high intraocular pressure when the pressure cannot be lowered by other means. measurement of glomerular filtration rate. - well established anuria due to severe renal disease. - severe pulmonary congestion or frank pulmonary edema. - active intracranial bleeding except during craniotomy. - severe dehydration. - progressive heart failure or pulmonary congestion after institution of mannitol therapy. - do not administer to patients with a known hypersensitivity to mannitol. to open tear outer wrap at notch and remove solution container. if supplemental medication is desired, follow directions below before preparing for administration. some opacity of the plastic due to moisture absorption during the sterilization process may be observed. this is normal and does not affect the solution quality or safety. the opacity will dimin

MANNITOL injection, solution USA - engelsk - NLM (National Library of Medicine)

mannitol injection, solution

icu medical inc. - mannitol (unii: 3owl53l36a) (mannitol - unii:3owl53l36a) - mannitol injection is indicated for the reduction of: - intracranial pressure and treatment of cerebral edema; - elevated intraocular pressure. mannitol injection is contraindicated in patients with: - known hypersensitivity to mannitol [see warnings and precautions (5.1)] - anuria [see warnings and precautions (5.2)] - severe hypovolemia [see warnings and precautions (5.4)] - pre-existing pulmonary vascular congestion or pulmonary edema [see warnings and precautions (5.5)] - active intracranial bleeding except during craniotomy. risk summary the available case report data with mannitol over decades of use have not identified a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes. mannitol crosses the placenta and may cause fluid shifts that could potentially result in adverse effects in the fetus (see data) . no adverse developmental effects from mannitol were reported in published animal studies; however, fluid shifts occurred in fetal ewes in response to mat